Biosimilars Hot Topic: Statistical Considerations for **Biosimilar Equivalence Trials**


A Comparative Clinical Efficacy and Safety Assessment is the **Final Stage of Demonstrating Biosimilarity Totality of evidence** · Biosimilars are approved based on the totality **Clinical trial** · The clinical trial aims to confirm that there are no clinically meaningful differences between a biosimilar and its reference product Clinical in a sensitive patient population using a pharmacology

The trial will also assess safety outcomes^{1,2}

of evidence1,2

sensitive endpoint^{1,2}

· Equivalence trials are recommended to confirm biosimilarity1,2



Biosimilar Development^{1,2}

During Equivalence Trial Design, a Step-by-step Approach is Used to Determine Equivalence Margins and Sample Size^{3,4}

Identification of study setting	Meta-analysis of historical data for the reference product	Determination of equivalence margins	Sample size
Sensitive population Sensitive endpoints	Size and variability of treatment effect is estimated	Based on estimated treatment effect size; represent the largest difference judged to be clinically acceptable	

Equivalence margins are determined independently for each proposed biosimilar, following discussion and agreement between regulators and the biosimilar developer.²





There are Two Common Statistical Measures Used to Assess Biosimilarity³

Risk difference (RD)

% of patients reaching endpoint with biosimilar - % reaching endpoint with reference product

• If drugs have the same efficacy, RD=0



Risk ratio (RR)


()

% of patients reaching endpoint with biosimilar % reaching endpoint with reference product

• If drugs have the same efficacy, RR=1



The Outcomes of RD and RR Analyses are Determined by the Predefined Equivalence Margins^{1,2,5}



CI, confidence interval

Comparative clinical efficacy is shown by demonstrating that the two-sided CI for RR or RD falls within the predefined equivalence margins.^{3,4,6}

References

1. EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf; 2. FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry, 2015. Available at: http://www.fda.gov; 3. Isakov L, et al. Am J Ther 2016;23:1903–10; 4. Alten R, et al. Semin Arthritis Rheum 2015;44:S2–8; 5. ICH. Topic E 9 statistical principles for clinical trials, 1998. Available at: https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Efficary/E9/Step4/H2B_Guideline.pdf 6. He J, et al. Clin Cancer Res 2016;22:5167–70. Links accessed February 2019



 (\mathbf{b})